Information

  • Dec 13, 2024

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh

  • Dec 13, 2024

US data has Fed striding toward rate cut next week, and tip-toeing into 2025

Investors view it as a near given that the U.S. Federal Reserve will cut interest rates by a quarter of a percentage point at its Dec. 17-18 meeting, with more attention focused on policymakers' new economic projections released alongside the decision. Those projections will include an updated look at how much further Fed officials think they will reduce rates in 2025 and perhaps into 2026, an exercise that will have to account for data in the meantime showing stickier-than-expected inflation, a healthy labor market, a U.S. election result that could shift the global trade and immigration landscape, and ongoing geopolitical risks. With so much to assess, a multitude of new risks, and a lot of uncertainty, many analysts expect the collective messaging from the central bank's policy statement on Wednesday, Fed Chair Jerome Powell's post-meeting press conference and the updated projections to be somewhat hawkish - with the Fed perhaps closer to a rate-cut stopping point, or at least very reluctant to commit to many more reductions in borrowing costs, than it was just a few months ago.

  • Dec 13, 2024

US data has Fed striding toward rate cut next week, and tip-toeing into 2025

Investors view it as a near given that the U.S. Federal Reserve will cut interest rates by a quarter of a percentage point at its Dec. 17-18 meeting, with more attention focused on policymakers' new economic projections released alongside the decision. Those projections will include an updated look at how much further Fed officials think they will reduce rates in 2025 and perhaps into 2026, an exercise that will have to account for data in the meantime showing stickier-than-expected inflation, a healthy labor market, a U.S. election result that could shift the global trade and immigration landscape, and ongoing geopolitical risks. With so much to assess, a multitude of new risks, and a lot of uncertainty, many analysts expect the collective messaging from the central bank's policy statement on Wednesday, Fed Chair Jerome Powell's post-meeting press conference and the updated projections to be somewhat hawkish - with the Fed perhaps closer to a rate-cut stopping point, or at least very reluctant to commit to many more reductions in borrowing costs, than it was just a few months ago.

  • Dec 13, 2024

Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst

BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024. Spending by pharmaceutical and biotech companies dropped after pandemic-related overspending, and demand in China stayed weak. This led some Life Sciences companies to lower their already-conservative fiscal year revenue forecasts as the year progressed. For most of fiscal year 2024, Life Sciences company valuations remained higher than pre-COVID levels but declined after the U.S. elections. Looking ahead

  • Dec 13, 2024

Crypto for Advisors: AI + Blockchain + Crypto

Blockchain is the key to unlocking a scalable, ethical, and user-focused AI economy, addressing critical barriers like resource demands, ethical concerns, and proof of humanhood.

  • Dec 13, 2024

Ciena's Strong 2025 Outlook Wins Analyst Confidence: AI Bandwidth And Optical Market Expansion In Focus

Ciena Corp (NYSE:CIEN) stock surged after BofA Securities upgraded it from Neutral to Buy and raised its price target from $70 to $95. Needham analyst Ryan Koontz maintained Ciena with a Buy and raised the price target from $80 to $95. Additionally, Northland Capital Markets, and Stifel raised their respective price targets on the stock. On Thursday, Ciena reported a fiscal fourth-quarter 2024 revenue decline of 0.5% to $1.12 billion, beating the analyst estimate of $1.10 billion. The adjusted E

  • Dec 13, 2024

General Mills To Gain Strength From Rebound In Pet Segment And Stabilizing Retail Growth, Analyst Upgrades Stock

BofA Securities analyst Peter T. Galbo upgraded General Mills, Inc. (NYSE:GIS) to Buy from Neutral, raising the price forecast to $80 from $78. The analyst suggests that General Mills is expected to return to organic sales growth at a faster and more sustainable rate compared to other center-store food peers. This growth will be driven by factors such as the re-acceleration in the Pet segment (specifically Blue Buffalo) and stabilization in North America Retail, as issues in the dough category a

Popular Post